Alumis (NASDAQ:ALMS) Trading 12.1% Higher on Analyst Upgrade

Shares of Alumis Inc. (NASDAQ:ALMS) were up 12.1% during mid-day trading on Tuesday after Oppenheimer raised their price target on the stock from $50.00 to $55.00. Oppenheimer currently has an outperform rating on the stock. Alumis traded as high as $22.03 and last traded at $22.6510. Approximately 561,143 shares traded hands during trading, a decline of 82% from the average daily volume of 3,085,917 shares. The stock had previously closed at $20.21.

A number of other equities analysts have also commented on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Alumis in a research note on Monday. Raymond James Financial initiated coverage on shares of Alumis in a research note on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 target price on the stock. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. UBS Group reiterated an “outperform” rating on shares of Alumis in a report on Tuesday, January 6th. Finally, Wells Fargo & Company upped their price target on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Alumis has a consensus rating of “Moderate Buy” and an average price target of $38.60.

Insider Activity at Alumis

In related news, major shareholder Foresite Labs, Llc bought 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was bought at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the insider directly owned 5,702,536 shares of the company’s stock, valued at approximately $96,943,112. This represents a 7.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Foresite Capital Management Vi purchased 411,764 shares of the stock in a transaction dated Thursday, January 8th. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the acquisition, the insider owned 5,702,536 shares in the company, valued at $96,943,112. This represents a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 1,823,527 shares of company stock worth $30,999,959 in the last 90 days. 40.70% of the stock is owned by corporate insiders.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target sharply to $55 and kept an “outperform” rating, signaling substantial upside vs. the current share level and supporting buying interest. Article Title
• Positive Sentiment: Chardan Capital reaffirmed its “buy” rating with a $38 price target, reiterating institutional conviction and adding support for bullish flows. Article Title
• Positive Sentiment: Morgan Stanley (via a TipRanks summary) maintained a Buy rating and $38 target, citing strong Phase‑3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a clinical/data catalyst that underpins upside expectations. Article Title
• Neutral Sentiment: HC Wainwright issued FY2027 EPS estimates of ($3.37) and kept a “Buy” rating with a $25 target — the EPS forecast is materially less negative than the consensus (-$8.51), which could be read as relatively constructive, but the figure is still negative and reflects ongoing cash burn/near‑term losses.
• Negative Sentiment: HC Wainwright cut its prior price target from $40 to $25 while retaining a buy rating, a mixed signal that reduces some upside expectations and may have pressured shorter‑term sentiment. Article Title
• Negative Sentiment: On 3/30 ALMS fell roughly 11% amid profit‑taking after a ~239% yearly gain; technical selling and traders locking gains were cited as drivers of the pullback. That short‑term volatility can amplify moves when headlines on ratings/targets hit the tape. Why Is Alumis Stock Falling Monday?

Institutional Trading of Alumis

Institutional investors have recently bought and sold shares of the company. Ieq Capital LLC lifted its holdings in shares of Alumis by 4.1% during the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock valued at $170,000 after buying an additional 690 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Alumis by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after buying an additional 979 shares during the last quarter. ProShare Advisors LLC increased its holdings in Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after buying an additional 1,618 shares during the last quarter. Stoneridge Investment Partners LLC raised its position in Alumis by 8.1% during the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock valued at $118,000 after acquiring an additional 2,210 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after acquiring an additional 2,949 shares in the last quarter.

Alumis Price Performance

The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -7.20 and a beta of -2.15. The stock’s 50 day simple moving average is $26.42 and its 200-day simple moving average is $14.79.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The business had revenue of $1.93 million for the quarter, compared to analyst estimates of $2.75 million. Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%. As a group, equities research analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current fiscal year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.